Detail akcie AxoGen online

Business Summary: Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, AxoGen Inc revenues increased 18% to $187.3M. Net loss decreased 54% to $10M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Peripheral nerves segment loss decrease of 85% to $3.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.51 to -$0.23.